BR0016409A - Processo para avaliar a sensibilidade do hiv a drogas - Google Patents
Processo para avaliar a sensibilidade do hiv a drogasInfo
- Publication number
- BR0016409A BR0016409A BR0016409-7A BR0016409A BR0016409A BR 0016409 A BR0016409 A BR 0016409A BR 0016409 A BR0016409 A BR 0016409A BR 0016409 A BR0016409 A BR 0016409A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- coding sequence
- protease
- recombinant
- molecular clone
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
- G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
- G01N2333/16—HIV-1, HIV-2
- G01N2333/161—HIV-1, HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p.7, p6, p66/68, p51/52, p31/34, p32, p40
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Physiology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
"PROCESSO PARA AVALIAR A SENSIBILIDADE DO HIV A DROGAS". é descrito um processo para avaliar a sensibilidade de uma variação de HIV proveniente de uma amostra biológica a pelo menos uma droga capaz de inibir a protease do HIV. O processo compreende as etapas de: a) amplificação do ácido nucléico que codifica a protease do HIV proveniente da amostra biológica, para se obter uma seq³ência codificadora da protease do HIV amplificada; b) clonagem da seq³ência codificadora da protease do HIV amplificada em um sítio de restrição único de um clone molecular modificado de HIV, em que o dito clone molecular modificado de HIV é modificado pelo menos através da deleção da seq³ência codificadora da protease e pela substituição da mesma pelo sítio de restrição único, para se obter um clone molecular recombinante de HIV que compreende e expressa a seq³ência codificadora da protease do HIV; c) introdução do clone molecular recombinante do HIV que compreende e expressa a seq³ência codificadora da protease do HIV em células cultivadas, para se obter células transfectadas com o HIV recombinante; d) medida do nível do antígeno p24 do HIV no sobrenadante das células transfectadas com o HIV recombinante tanto na presença quanto na ausência da droga capaz de inibir a protease do HIV. O processo é adequado para qualquer variação de HIV, para variações de HIV-1 ou de HIV-2. São também descrito kits para diagnóstico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99830776A EP1109019A1 (en) | 1999-12-15 | 1999-12-15 | Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease |
PCT/IT2000/000518 WO2001044508A2 (en) | 1999-12-15 | 2000-12-14 | Method to evaluate the sensitivity of hiv variants to drugs able to inhibit the hiv protease |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0016409A true BR0016409A (pt) | 2002-08-20 |
Family
ID=8243712
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0016409-7A BR0016409A (pt) | 1999-12-15 | 2000-12-14 | Processo para avaliar a sensibilidade do hiv a drogas |
Country Status (9)
Country | Link |
---|---|
US (1) | US20030175690A1 (pt) |
EP (2) | EP1109019A1 (pt) |
AT (1) | ATE265043T1 (pt) |
AU (1) | AU2395101A (pt) |
BR (1) | BR0016409A (pt) |
CA (1) | CA2393620A1 (pt) |
DE (1) | DE60010127D1 (pt) |
RU (1) | RU2002118706A (pt) |
WO (1) | WO2001044508A2 (pt) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
CA2472438A1 (en) * | 2002-06-28 | 2004-01-08 | Fuso Pharmaceutical Industries, Ltd. | Mannose binding protein for use in anti-hiv treatment |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5571666A (en) * | 1988-10-28 | 1996-11-05 | Oklahoma Medical Research Foundation | Thiazine dyes used to inactivate HIV in biological fluids |
CN1209875A (zh) * | 1996-01-26 | 1999-03-03 | 维科公司 | 根据人类hiv病毒株的表型药物敏感性控制hiv阳性病人化疗的方法 |
-
1999
- 1999-12-15 EP EP99830776A patent/EP1109019A1/en not_active Withdrawn
-
2000
- 2000-12-14 BR BR0016409-7A patent/BR0016409A/pt not_active Application Discontinuation
- 2000-12-14 AT AT00987612T patent/ATE265043T1/de not_active IP Right Cessation
- 2000-12-14 CA CA002393620A patent/CA2393620A1/en not_active Abandoned
- 2000-12-14 WO PCT/IT2000/000518 patent/WO2001044508A2/en active IP Right Grant
- 2000-12-14 US US10/149,575 patent/US20030175690A1/en not_active Abandoned
- 2000-12-14 AU AU23951/01A patent/AU2395101A/en not_active Abandoned
- 2000-12-14 DE DE60010127T patent/DE60010127D1/de not_active Expired - Lifetime
- 2000-12-14 RU RU2002118706/15A patent/RU2002118706A/ru unknown
- 2000-12-14 EP EP00987612A patent/EP1242818B1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
DE60010127D1 (de) | 2004-05-27 |
RU2002118706A (ru) | 2004-02-27 |
WO2001044508A3 (en) | 2002-01-03 |
WO2001044508A2 (en) | 2001-06-21 |
EP1242818A2 (en) | 2002-09-25 |
ATE265043T1 (de) | 2004-05-15 |
EP1109019A1 (en) | 2001-06-20 |
AU2395101A (en) | 2001-06-25 |
US20030175690A1 (en) | 2003-09-18 |
CA2393620A1 (en) | 2001-06-21 |
EP1242818B1 (en) | 2004-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Bushman et al. | Activities of human immunodeficiency virus (HIV) integration protein in vitro: specific cleavage and integration of HIV DNA. | |
Wu et al. | Extrachromosomal DNA: an emerging hallmark in human cancer | |
DK1280898T3 (da) | Modificerede ES-celler og ES-cellespecifikt gen | |
DE69635864D1 (de) | Rekombinante rna-replikase von hepatitis-c-virus | |
ATE421999T1 (de) | Nachweis von hiv-1 durch amplifizierung von nukleinsäuren | |
AR247761A1 (es) | Metodo para producir un polipeptido en una celula hospedante de kluyveromyces, dicha celula hospedante transformada y secuencia a adn empleada | |
Semaan et al. | Cytotoxic effects during knock out of multiple porcine endogenous retrovirus (PERV) sequences in the pig genome by zinc finger nucleases (ZFN) | |
ATE466932T1 (de) | Vermehrung von viren in zellkultur | |
ES2045932T3 (es) | Procedimiento para la deteccion de secuencias especificas de acidos nucleicos y sus aplicaciones. | |
US20240102084A1 (en) | Compositions and methods for detection of a nucleic acid | |
DK0675959T3 (da) | DNA amplificering | |
Lee et al. | Highly sensitive immuno-CRISPR assay for CXCL9 detection | |
CN113564149A (zh) | 一种三联体融合蛋白及其在病毒自剪切蛋白酶抑制剂活性评估和筛选时的应用 | |
Nappi et al. | Identification of a novel posttranscriptional regulatory element by using a rev-and RRE-mutated human immunodeficiency virus type 1 DNA proviral clone as a molecular trap | |
ATE513851T1 (de) | Menschliches gen zur fruchtbarkeit entscheidend | |
DE69833660D1 (de) | Nukleinsäuresonden zur detektion von candida-spezies | |
Heilmann et al. | A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition | |
Wang et al. | RNA− Protein Interactions in the Tat− trans-Activation Response Element Complex Determined by Site-Specific Photo-Cross-Linking | |
Lin et al. | Study on Factors Affecting the Performance of a CRISPR/Cas-Assisted New Immunoassay: Detection of Salivary Insulin as an Example | |
BR0016409A (pt) | Processo para avaliar a sensibilidade do hiv a drogas | |
Rojo-Romanos et al. | Precise excision of HTLV-1 provirus with a designer-recombinase | |
ES2054769T3 (es) | Polipeptidos hiv-2 recombinantes. | |
Tamilarasu et al. | A new strategy for site-specific protein modification: analysis of a tat peptide− TAR RNA interaction | |
He et al. | Synthetic circuit-driven expression of heterologous enzymes for disease detection | |
FR2600079B1 (fr) | Vecteur viral et adn recombinant codant pour la proteine f du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la proteine, proteine obtenue, vaccin et anticorps obtenus |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |